Reports & Testimonies

  • GAO’s recommendations database contains report recommendations that still need to be addressed.

    GAO’s recommendations help congressional and agency leaders prepare for appropriations and oversight activities, as well as help improve government operations. Recommendations remain open until they are designated as Closed-implemented or Closed-not implemented. You can explore open recommendations by searching or browsing.

    GAO's priority recommendations are those that we believe warrant priority attention. We sent letters to the heads of key departments and agencies, urging them to continue focusing on these issues. These recommendations are labeled as such. You can find priority recommendations by searching or browsing our open recommendations below, or through our mobile app.

  • Browse Open Recommendations

    Explore priority recommendations by subject terms or browse by federal agency

    Search Open Recommendations

    Search for a specific priority recommendation by word or phrase



  • Governing on the go?

    Our Priorities for Policy Makers app makes it easier for leaders to search our recommendations on the go.

    See the November 10th Press Release


  • Have a Question about a Recommendation?

    • For questions about a specific recommendation, contact the person or office listed with the recommendation.
    • For general information about recommendations, contact GAO's Audit Policy and Quality Assurance office at (202) 512-6100 or apqa@gao.gov.
  • « Back to Results List Sort by   

    Results:

    Subject Term: "Research and development facilities"

    5 publications with a total of 12 open recommendations
    Director: Elizabeth H. Curda
    Phone: (202) 512-7114

    3 open recommendations
    Recommendation: In order to ensure that the agency is adequately protecting the White Oak campus as a designated high-risk facility and strategically planning for the White Oak campus's future, as FDA moves forward with its proposed planning efforts, the Commissioner of FDA, in consultation with the Administrator of GSA, should implement vehicular access control measures on the White Oak campus to meet the requirements of the high-risk facility level designation assigned in the 2014 risk assessment report, or fully document the rationale for any deviations from these requirements.

    Agency: Department of Health and Human Services: Food and Drug Administration
    Status: Open

    Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
    Recommendation: In order to ensure that the agency is adequately protecting the White Oak campus as a designated high-risk facility and strategically planning for the White Oak campus's future, as FDA moves forward with its proposed planning efforts, the Commissioner of FDA, in consultation with the Administrator of GSA, should further incorporate leading strategic facilities planning practices into FDA's proposed planning efforts by ensuring that FDA establish strategic linkage between its strategic priorities and its facilities plans.

    Agency: Department of Health and Human Services: Food and Drug Administration
    Status: Open

    Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
    Recommendation: In order to ensure that the agency is adequately protecting the White Oak campus as a designated high-risk facility and strategically planning for the White Oak campus's future, as FDA moves forward with its proposed planning efforts, the Commissioner of FDA, in consultation with the Administrator of GSA, should document the key information related to daily operational activities and ongoing benefits and challenges that are needed to inform FDA's proposed planning efforts in the areas of needs assessment, gap identification, and alternatives analysis, and incorporate into proposed planning efforts a detailed strategy for collecting and analyzing this information.

    Agency: Department of Health and Human Services: Food and Drug Administration
    Status: Open

    Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
    Director: Joseph Kirschbaum
    Phone: (202) 512-9971

    3 open recommendations
    Recommendation: To improve the identification, alignment, and management of DOD's chemical and biological defense infrastructure and to fully institutionalize the use of risk assessments to support future investment decisions, the Secretary of Defense should direct the Under Secretary of Defense for Acquisition, Technology and Logistics to update the roles and responsibilities guidance in DOD Directive 5160.05E to identify which organizations are responsible for conducting and participating in CBDP Enterprise risk assessments.

    Agency: Department of Defense
    Status: Open

    Comments: DOD concurred with this recommendation but has not yet completed actions to implement it. As of August 2017, DOD was still waiting to release the final version of DOO Directive 5160.05E.
    Recommendation: To improve the identification, alignment, and management of DOD's chemical and biological defense infrastructure and to fully institutionalize the use of risk assessments to support future investment decisions, the Secretary of Defense should direct the Under Secretary of Defense for Acquisition, Technology and Logistics to update the CBDP Enterprise's portfolio planning process, to include when risk assessments will be conducted.

    Agency: Department of Defense
    Status: Open

    Comments: DOD concurred with this recommendation but has not yet completed actions to implement it. On 6/8/16, DOD reported that the risk assessment process was initially piloted in 2014 to determine its utility for informing CBDP Enterprise portfolio planning and guidance. Moving forward, the CBDP Enterprise plans to conduct risk assessments annually to support portfolio planning and guidance. As of August 2017, DOD reported that the department was beginning an approximately 12-month process to revise the CBDP Business Plan, which would likely be published as a DOD Instruction. This plan should address the risk assessment recommendation.
    Recommendation: To improve the identification, alignment, and management of DOD's chemical and biological defense infrastructure and to enhance PAIO's ongoing analysis of potential infrastructure duplication in the CBDP Enterprise and gain potential efficiencies, the Secretary of Defense should direct the Under Secretary of Defense for Acquisition, Technology and Logistics to identify, request, and consider any information from existing infrastructure studies from other federal agencies with chemical and biological research and development and test and evaluation infrastructure.

    Agency: Department of Defense
    Status: Open

    Comments: DOD concurred with this recommendation but has not yet completed actions to implement it. As of July 2017, DOD has requested, but not received, such studies from other federal agencies. However, DOD is currently engaged in phase two of a three-phase effort regarding its chemical and biological defense infrastructure program (CBDP), which includes a review of the department's interagency roles and responsibilities for its chemical and biological defense Infrastructure Manager. Targeted completion for this phase is December 2017, at which time, DOD may have obtained relevant information from other federal agencies.
    Director: Mak, Marie A
    Phone: (202) 512-4841

    1 open recommendations
    Recommendation: In order for NASA to fully implement the NASA Authorization Act of 2008 and for CASIS to fulfill its responsibility as outlined in the cooperative agreement, the NASA Administrator should direct the Associate Administrator for the Human Exploration and Operations Mission Directorate to fully staff the ISS National Laboratory Advisory Committee.

    Agency: National Aeronautics and Space Administration
    Status: Open

    Comments: NASA does not plan to staff the International Space Station National Laboratory Advisory Committee (INLAC) at this time. Officials stated that they continue to believe that the Center for the Advancement of Science in Space (CASIS) Board of Directors meets the intent of the INLAC charter by providing oversight of CASIS implementation of utilization of the ISS as a national laboratory. NASA remains concerned about staffing another oversight group that may create conflicts with the existing CASIS Board of Directors. NASA is also exploring with CASIS opportunities to open portions of board meetings to the general public and interested parties in order to foster additional transparency and a broad and free exchange of ideas. In response to this recommendation, the Associate Administrator for the Human Exploration and Operations Mission Directorate indicated that NASA was seeking relief from the statutory requirement to staff the INLAC.
    Director: John Neumann
    Phone: (202) 512-3841

    4 open recommendations
    Recommendation: To more effectively fulfill its expanded role in providing a clearinghouse of information on available federal technology transfer opportunities, the Chair of FLC, in coordination with the other members of the Executive Board, should work collaboratively with agency and lab members to take steps to better communicate with potential customers during the design and implementation of FLC's clearinghouse initiatives, including conducting customer needs assessments, conducting customer testing of current and future web-based initiatives, and collecting customer feedback on all FLC initiatives to make the initiatives more useful.

    Agency: Federal Laboratory Consortium for Technology Transfer
    Status: Open

    Comments: FLC has provided GAO with information on steps they are taking to address the recommendations in GAO-15-127. A number of these actions should be completed towards the end of 2016 after which we plan to request additional information from FLC.
    Recommendation: To more effectively fulfill its expanded role in providing a clearinghouse of information on available federal technology transfer opportunities, the Chair of FLC, in coordination with the other members of the Executive Board, once feedback is collected from potential customers, should work collaboratively with agency and lab members to use this feedback to improve FLC's initiatives to make them more useful to potential customers, including asking FLC members for additional or different information, as appropriate.

    Agency: Federal Laboratory Consortium for Technology Transfer
    Status: Open

    Comments: FLC has provided GAO with information on steps they are taking to address the recommendations in GAO-15-127. A number of these actions should be completed towards the end of 2016 after which we plan to request additional information from FLC.
    Recommendation: To more effectively fulfill its expanded role in providing a clearinghouse of information on available federal technology transfer opportunities, the Chair of FLC, in coordination with the other members of the Executive Board, should work collaboratively with agency and lab members to develop performance goals and measures for FLC's clearinghouse initiatives and use the results to evaluate progress toward meeting FLC's goals on outreach and networking.

    Agency: Federal Laboratory Consortium for Technology Transfer
    Status: Open

    Comments: FLC has provided GAO with information on steps they are taking to address the recommendations in GAO-15-127. A number of these actions should be completed towards the end of 2016 after which we plan to request additional information from FLC.
    Recommendation: To more effectively fulfill its expanded role in providing a clearinghouse of information on available federal technology transfer opportunities, the Chair of FLC, in coordination with the other members of the Executive Board, should report on FLC's progress in these efforts in its annual report to the President and Congress.

    Agency: Federal Laboratory Consortium for Technology Transfer
    Status: Open

    Comments: FLC has provided GAO with information on steps they are taking to address the recommendations in GAO-15-127. A number of these actions should be completed towards the end of 2016 after which we plan to request additional information from FLC.
    Director: Kohn, Linda T
    Phone: (202) 512-7114

    1 open recommendations
    Recommendation: To help address the uncertainty NIH faces, related to the potential impact of increasing indirect costs on its funding of future research, the Director of NIH should assess the impact of growth in indirect costs on its research mission, including, as necessary, planning for how to deal with potential future increases in indirect costs that could limit the amount of funding available for total research, including the direct costs of research projects.

    Agency: Department of Health and Human Services: Public Health Service: National Institutes of Health
    Status: Open

    Comments: As of July 7, 2015, NIH provided some information indicating that it had taken action to address our recommendation by tracking the size of indirect costs as a proportion of NIH's overall budget as part of the agency's annual budget planning process and risk assessment program. However, we determined that the actions did not fully address the recommendation because they focus on the agency's overall budget and do not assess the potential ongoing impact of indirect costs for universities on its mission. As of August 2017, NIH officials have not informed us of any additional actions taken to implement this recommendation. We will update the status of this recommendation when we receive additional information.